Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Hoffman

Physician Assistant, Medical Mesa, AZ Physician Assistant

NPI 1508142670 CMS profile 10563888

1500 S. Dobson Road, Suite 202, Mesa, AZ 85202

Open in the dashboard

General payments

$13,613

682 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Hoffman of Mesa, AZ is reported in the CMS Open Payments database as having received $13,613 across 682 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,690 83
2024 General $3,059 140
2023 General $3,206 151
2022 General $2,939 142
2021 General $2,718 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Hoffman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Dana Hoffman were reported at $1,690. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Dana Hoffman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,718 $156 $41–$563 $132
2022 $2,939 $185 $55–$649 $149
2023 $3,206 $199 $58–$717 $160
2024 $3,059 $206 $62–$740 $164
2025 $1,690 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,381 155 payments
  2. Amgen Inc. $3,014 174 payments
  3. UCB, Inc. $1,381 42 payments
  4. Pfizer Inc. $1,340 88 payments
  5. Janssen Biotech, Inc. $641 34 payments
  6. Lilly USA, LLC $565 36 payments
  7. GlaxoSmithKline, LLC. $417 24 payments
  8. Novartis Pharmaceuticals Corporation $380 21 payments
  9. Genzyme Corporation $324 10 payments
  10. E.R. Squibb & Sons, L.L.C. $281 12 payments
  11. Other $1,890 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,514 681 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $2,570 118 payments
  2. XELJANZ $1,318 87 payments
  3. Enbrel Inflammation $1,277 64 payments
  4. Otezla $1,083 67 payments
  5. Cimzia $1,006 31 payments
  6. Enbrel Inflammation $774 49 payments
  7. TALTZ $565 36 payments
  8. TREMFYA $536 25 payments
  9. BENLYSTA $417 24 payments
  10. INFLECTRA $402 32 payments
  11. Other $6,682 350 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

894

Median for Physician Assistant: 241

Drug cost

$282,889

Median for Physician Assistant: $4,110

Branded share of claims

31.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $158,740
Rinvoq Upadacitinib Brand 16 $100,327
Methotrexate Methotrexate Sodium Brand 255 $6,722
Hydroxychloroquine Sulfate Generic 131 $5,996
Leflunomide Generic 73 $5,169
Pilocarpine Hcl Generic 14 $1,888
Gabapentin Generic 55 $1,103
Allopurinol Generic 62 $859
Folic Acid Generic 50 $583
Prednisone Generic 106 $456

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $498
$498 16 —
Cimzia
  • UCB, Inc. $342
$342 — —
XELJANZ
  • PFIZER INC. $253
$253 — —
SKYRIZI
  • AbbVie, Inc. $227
$227 — —
Enbrel
  • Amgen Inc. $220
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

682 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record